- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04474210
A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants
An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-56136379 in Adult Participants
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Texas
-
San Antonio, Texas, United States, 78215
- The Texas Liver Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index (BMI) (kilograms [kg]/height [m]^2) between 18.0 and 38.0 kilogram/meter^2 (kg/m2) (inclusive), and body weight not less than (<) 50 kg
Participants with normal renal function:
- Have normal renal function defined as estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter/minute computed with the online calculator on the CKD-EPI website by use of the Chronic Kidney Disease Epidemiology Collaboration creatinine clearance (CKD-EPIcr) result
- Must have stable renal function as defined as: (a) for participants with impaired renal function: <20 percent (%) change in serum creatinine concentrations between screening and Day -1; (b) for healthy participants: a change in serum creatinine concentration <0.2 milligram per deciliter (mg/dL) between screening and Day -1
Participants with renal impairment:
- Have an impaired renal function based on eGFR as(eGFR computed with the online calculator on the CKD-EPI website providing eGFR (in mL/min units) by use of the CKD-EPIcr result: (a) eGFR <90 to 60 mL/minute for participants in Group 3 (mild renal impairment cohort); (b) eGFR 30 to 59 mL/minute for participants in Group 4 (moderate renal impairment cohort); (c) eGFR <30 mL/minute but not yet on hemodialysis, for participants in Group 1 (severe renal impairment and/or kidney failure); (d) eGFR <15 mL/minute and on hemodialysis, for participants in Group 5 (kidney failure)
- Concomitant medications to treat underlying disease states or medical conditions related to renal impairment are allowed. Participants must be on a stable dose of medication and/or treatment regimen for at least 2 months (3 months for thyroid hormone replacement therapy [HRT]) before dosing as well as during the study
Exclusion Criteria:
- Individuals who take creatine supplements, have a non-standard muscle mass such as amputation, malnutrition, or muscle wasting; because these factors are not accounted for in the prediction equations for GFR chronic kidney disease epidemiology collaboration (CKD EPI)
Participants with normal renal function:
- Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or Day -1, as deemed appropriate by the investigator
- Clinically significant abnormal physical examination, vital signs, body temperature, or 12 lead ECG at screening or Day -1, as deemed appropriate by the investigator
Participants with renal impairment:
- Evidence of clinically apparent concurrent disease based upon complete clinical laboratory testing, full physical examination, or medical history, except for controlled hypertension and those problems directly associated with the primary diagnosis of renal impairment
- Any clinically significant laboratory abnormality except abnormalities that may be caused by renal impairment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: Group 1
Participants with severe renal impairment and/or kidney failure (estimated glomerular filtration rate [eGFR] less than [<] 30 milliliter[mL]/minute but not yet on hemodialysis) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Active Comparator: Part A: Group 2
Healthy participants with normal renal function (eGFR greater than or equal to [>=] 90 mL/minute), will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Experimental: Part B: Group 3 (Optional)
Participants with mild renal impairment (eGFR: 60 to 89 mL/minute) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Experimental: Part B: Group 4 (Optional)
Participants with moderate renal impairment (eGFR: 30 to 59 mL/minute) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Experimental: Part B: Group 5 (Optional)
Participants with kidney failure (eGFR: <15 mL/minute and on hemodialysis; pharmacokinetic [PK] to be evaluated during non-dialysis days) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Analyte Concentration (Cmax)
Time Frame: Up to Day 29
|
Cmax is defined as the maximum observed plasma analyte concentration.
|
Up to Day 29
|
Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax)
Time Frame: Up to Day 29
|
Tmax is defined as the actual sampling time to reach the maximum observed plasma analyte concentration.
|
Up to Day 29
|
Area Under the Analyte Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC [0-24])
Time Frame: Up to 24 hours postdose
|
AUC (0-24) is defined as area under the analyte concentration-time curve (AUC) from time 0 to 24 hours postdose, calculated by linear-linear trapezoidal summation.
|
Up to 24 hours postdose
|
Area Under the Analyte Concentration-time Curve From Time Zero to 144 Hours Postdose (AUC [0-144])
Time Frame: Up to 144 hours postdose
|
AUC (0-144) is defined as AUC from time 0 to 144 hours postdose, calculated by linear-linear trapezoidal summation.
|
Up to 144 hours postdose
|
Area Under the Analyte Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC [0-last])
Time Frame: Up to Day 29
|
AUC (0-last) is defined as AUC from time 0 to the time of the last measurable (non-below quantification limit [non-BQL]) concentration, calculated by linear-linear trapezoidal summation.
|
Up to Day 29
|
Area Under the Analyte Concentration-time Curve From Time Zero to Infinity (AUC [0-infinity])
Time Frame: Up to Day 29
|
AUC (0-infinity) is defined as AUC from time 0 to infinity, calculated as the sum of AUC (0-last) and C(last)/lambda(z); where C(last) is the last observed measurable (non-BQL) concentration; and lambda(z) is apparent terminal elimination rate constant.
|
Up to Day 29
|
Total Apparent Oral Clearance (CL/F)
Time Frame: Up to Day 29
|
CL/F is defined as total apparent oral clearance, calculated as dose/AUC (0-infinity).
|
Up to Day 29
|
Apparent Volume of Distribution (Vd/F)
Time Frame: Up to Day 29
|
Vd/F is defined as apparent volume of distribution, calculated as dose/[lambda (z)*AUC (0-infinity)].
|
Up to Day 29
|
Apparent Terminal Elimination Rate Constant (Lambda[z])
Time Frame: Up to Day 29
|
Lambda(z) is defined as apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log-transformed concentration vs time curve.
|
Up to Day 29
|
Apparent Terminal Elimination Half-life (t1/2)
Time Frame: Up to Day 29
|
t1/2 is defined as apparent terminal elimination half-life, calculated as 0.693/lambda(z).
|
Up to Day 29
|
Percentage of JNJ-56136379 Excreted in Urine (Ae,%Dose)
Time Frame: Up to Day 7
|
Ae,%Dose is defined as cumulative urinary recovery represented as a percentage of dose, calculated as 100*(Aetotal/Dose).
|
Up to Day 7
|
Renal Clearance (CLr)
Time Frame: Up to 144 hours postdose
|
CLr is defined as renal clearance, calculated as Ae(0-144h)/AUC(144h).
|
Up to 144 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: Up to 8 weeks
|
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
Up to 8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108802
- 56136379HPB1010 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Insufficiency
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
CHU de ReimsUnknownChronic Renal InsufficiencyFrance
-
BiocodexNot yet recruitingChronic Renal InsufficiencyBulgaria
-
Novartis PharmaceuticalsCompletedChronic Renal InsufficiencyUnited States
-
Weill Medical College of Cornell UniversityGenentech, Inc.SuspendedChronic Renal InsufficiencyUnited States
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)CompletedAcute Renal Failure | Chronic Renal InsufficiencyAustria
-
Azienda Sanitaria ASL Avellino 2UnknownChronic Renal InsufficiencyItaly
-
Assistance Publique Hopitaux De MarseilleCompletedChronic Renal InsufficiencyFrance
Clinical Trials on JNJ-56136379
-
Janssen Sciences Ireland UCCompletedHepatitis B, ChronicBelgium, United States, Japan, Korea, Republic of, France, Hong Kong, Canada, Italy, Thailand, Germany, Malaysia, Spain, Russian Federation, Turkey, United Kingdom, Poland, Brazil, Czechia, China
-
Janssen Research & Development, LLCCompleted
-
Janssen Sciences Ireland UCCompletedHepatitis BUnited States, Korea, Republic of, France, Belgium, Italy, Taiwan, United Kingdom, Thailand, Malaysia, China, Spain, Canada, Germany, Japan, Russian Federation, Turkey, Ukraine, Poland, Hong Kong
-
Janssen Sciences Ireland UCCompletedHealthy | Hepatitis, ChronicFrance, Taiwan, Spain, Belgium, Bulgaria, Malaysia, Romania, Germany, Georgia, Moldova, Republic of
-
Janssen Research & Development, LLCCompleted
-
Janssen Sciences Ireland UCCompleted
-
Janssen Sciences Ireland UCCompletedHepatitis B, ChronicBelgium, United Kingdom, France, Italy, Germany, Spain, Poland
-
Janssen Research & Development, LLCCompletedHepatitis B, ChronicFrance, Taiwan, Canada, United States, Germany, Spain, Japan, Russian Federation, Turkey, United Kingdom
-
Ottawa Hospital Research InstituteUnknownMeibomian Gland Dysfunction | BlepharitisCanada
-
Janssen Research & Development, LLCCompletedHepatitis BFrance, United States, Belgium, United Kingdom, Poland, New Zealand, Germany, Italy, Canada